



IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application**

Inventor(s): Bagchi et al.

Appln. No.: 10/805,129

Conf. No.: 8914

Filed: March 19, 2004

Title: METHOD AND COMPOSITION FOR  
DECREASING GHRELIN LEVELS**PATENT APPLICATION**

Art Unit: 1614

Examiner: Weddington, Kevin E.

Atty. Docket No.: IHEL-01040US1

**Customer No. 23910****CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence is being deposited in the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**, on the date shown below.

Mathew Otts (Signature)

Mathew Otts

Signature Date: 12/2/2005**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

***Enclosed with this statement are the following:***

- X Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.
- X Copies of cited U.S. patents and publications are not enclosed. However, copies of cited foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98(a)(2), as required.
- X If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. MPEP §609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement, 37 C.F.R. §1.98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).

— **PTA Statement under 37 C.F.R. §1.704(d).** Each item of information contained in the *Information Disclosure Statement* was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the *Information Disclosure Statement*.

***This statement should be considered because:***

X **37 C.F.R. §1.97(b).** This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:


- (1) It is being filed within three months of the filing date of an application other than a continued prosecution application under § 1.53(d);  
-- OR --
- (2) It is being filed within 3 months of entry of a national stage;  
-- OR --
- (3) It is being filed before the mailing date of the first Office Action on the merits,  
-- OR --
- (4) It is being filed before the mailing date of the first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

X ***Fee Authorization.*** The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325. ***A duplicate copy of this authorization is enclosed.***


Respectfully submitted,

FLIESLER MEYER LLP

Date: 12/2/2005

By:   
Anthony G. Craig  
Reg. No. 50,342

FLIESLER MEYER LLP  
Four Embarcadero Center, Fourth Floor  
San Francisco, California 94111-4156  
Telephone: (415) 362-3800  
Facsimile: (415) 362-2928  
Customer No. 23910

Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>Information Disclosure Statement</b> APPLICANT (Use several sheets if necessary) 	Attorney Docket Number <b>IHEAL-01040US1</b>	Serial/Patent Number <b>10/805,129</b>
	Applicant/Patent Owner <b>Bagchi et al.</b>	
	Filing/Issue Date <b>March 19, 2004</b>	Group Art Unit <b>1614</b>

<b>U.S. PATENTS</b>
---------------------

Examiner Initial	Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date

<b>U.S. PATENT PUBLICATIONS</b>
---------------------------------

Examiner Initial	Patent Application Publication Number	Publication Date	Applicant

<b>PENDING U.S. PATENT APPLICATIONS</b>
---

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes   No

<b>FOREIGN PATENT DOCUMENTS</b>
---------------------------------

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	WO 00/48983	08/24/2000	PCT			
	JP2002306130	10/22/2002	Japan			X
	WO 02/078616	10/10/2002	PCT			
	Int'l Search Report for PCT/US04/08474	08/18/2005	PCT			

<b>OTHER DOCUMENTS</b> (Include author (if any), title, publisher and place of publication, date and pertinent pages)
---

	Shara, M., et al., "Dose- and Time-Dependent Effects of a Novel (-)-Hydroxycitric Acid Extract on Body Weight, Hepatic and Testicular Lipid Peroxidation, DNA Fragmentation and Histopathological Data Over a Period of 90 Days," <i>Mol Cell Biochem.</i> Dec. 2003; 254(1-2); pp. 339-346.